Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain
- Conditions
- Ankle Sprain
- Interventions
- Drug: Placebo
- Registration Number
- NCT01255423
- Lead Sponsor
- Novartis
- Brief Summary
The purpose of this study is to evaluate the efficacy of Diclofenac Sodium Topical (DSG) 1% compared with placebo applied four times a day in subjects with acute ankle sprains under 'in-use' conditions, in particular with regard to pain relief.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 206
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Diclofenac sodium topical gel 1% Diclofenac sodium topical gel 1% - Placebo Placebo -
- Primary Outcome Measures
Name Time Method Pain on Movement 72 hours Pain on movement at 72 hours assessed on a 100 mm visual analog scale with anchors at 0= "No pain" and 100= "Extreme pain"
- Secondary Outcome Measures
Name Time Method Pain on Movement 24 hours and 7 days Pain on movement at 24 hours and 7 days assessed on a 100 mm visual analog scale with anchors at 0= "No pain" and 100= "Extreme pain"
Onset of Pain Relief Day 1 Onset of perceptible pain relief
Tenderness Change from baseline at 24 and 72 hours, 7 days Tenderness at 24 and 72 hours and 7 days. Change from baseline. Tenderness was measured by a calibrated algometer in order to quantify the pressure pain threshold, a measure of tenderness.
Ankle Joint Function 24 and 72 hours, 7 days Ankle joint function score (Karlsson Scoring scale which ranges from 0 "worst possible score" to 90 "best possible score")at 24 and 72 hours and 7 days.